dotMD.com
Find a Doctor
Health Research, In Plain English • 5,828 Stories

Medical breakthroughs, translated for real life.

Every story explains a peer-reviewed clinical trial or medical journal report at a clear, 8th-grade reading level—with 15-second takeaways, participant counts, Study Rigor Scores, and a direct link to the formal paper.

All Research Stories Phase III Randomized Trial (3,355) Randomized Controlled Trial (1,799) Meta-Analysis (566) Peer-Reviewed Journal (Clinical Trials) (39) FDA Drug Recall (Class II) (15) Completed Human Clinical Trial (NCT) (15) FDA Safety Alert (13) FDA Recall (12) Peer-Reviewed Journal (Longevity & Biotech) (8) Clinical Trial (4) Clinical Pharmacology Review (1) Systematic Review (1)
Live Journal & Safety Desks: JAMA Network New England Journal of Medicine The Lancet BMJ Recent Research Nature Medicine FDA MedWatch Safety Alerts FDA Drug Recalls
Peer-Reviewed Journal (Longevity & Biotech) • Nature Medicine • 2026-10-30

Can This Approach Help? Inside the Latest Research on Climate change threatens malaria elimination in the Asia

Nature Medicine, Published online: 30 October 2026; doi:10.1038/s41591-026-04722-x A multidisciplinary group of policymakers and researchers discusses the impacts of climate change on malaria in the Asia Pacific, identifies gaps in national adaptation strategi

Read Plain-English Story | Formal Study: “Climate change threatens malaria elimination in the Asia Pacific”
Rigor 94/100
Formal Study (PMID #NATURE_MED-3409289587)
Peer-Reviewed Journal (Longevity & Biotech) • Nature Medicine • 2026-10-29

Can This Approach Help? Inside the Latest Research on A small-molecule TREM2 agonist for Alzheimer’s

Nature Medicine, Published online: 29 October 2026; doi:10.1038/d41591-026-00055-x Preclinical analysis and a phase 1 trial support VG-3927 as a promising drug candidate for Alzheimer’s disease, demonstrating successful penetration of the central nervous syste

Read Plain-English Story | Formal Study: “A small-molecule TREM2 agonist for Alzheimer’s disease”
Rigor 96/100
Formal Study (PMID #NATURE_MED-2455937869)
Peer-Reviewed Journal (Longevity & Biotech) • Nature Medicine • 2026-10-29

Can This Approach Help? Inside the Latest Research on Insights into early-onset colorectal cancer from a single-nucleus RNA-seq atlas

Nature Medicine, Published online: 29 October 2026; doi:10.1038/s41591-026-04721-y A high-resolution snRNA-seq atlas of 189 colorectal tumors from patients aged 20–90+ years uncovers age-associated features of colorectal cancer.

Read Plain-English Story | Formal Study: “Insights into early-onset colorectal cancer from a single-nucleus RNA-seq atlas of colorectal cancer across the age continuum”
Rigor 95/100
Formal Study (PMID #NATURE_MED-1670580688)
Peer-Reviewed Journal (Longevity & Biotech) • Nature Medicine • 2026-10-29

Can This Approach Help? Inside the Latest Research on Applying digital twins to prevent preterm

Nature Medicine, Published online: 29 October 2026; doi:10.1038/d41591-026-00056-w Researchers developed a digital twin framework to safely evaluate the effects of drugs on the immune system and time to labor, which could enable personalized interventions to p

Read Plain-English Story | Formal Study: “Applying digital twins to prevent preterm births”
Rigor 93/100
Formal Study (PMID #NATURE_MED-1139469654)
Peer-Reviewed Journal (Longevity & Biotech) • Nature Medicine • 2026-10-29

Can This Approach Help? Inside the Latest Research on 5-year outcomes of chemotherapy de-escalation in HER2-positive early breast

Nature Medicine, Published online: 29 October 2026; doi:10.1038/s41591-026-04723-w A 5-year secondary analysis of the phase 2 PHERGain trial supports the clinical utility of a PET-guided adaptive strategy for treatment de-escalation in HER2-positive early brea

Read Plain-English Story | Formal Study: “5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial”
Rigor 92/100
Formal Study (PMID #NATURE_MED-4248748391)
Peer-Reviewed Journal (Longevity & Biotech) • Nature Medicine • 2026-10-29

Can This Approach Help? Inside the Latest Research on A clinical multimodal vision language foundation model with fine-grain

Nature Medicine, Published online: 29 October 2026; doi:10.1038/s41591-026-04655-5 A multimodal vision language foundation model, EVLF-FM, integrates extensive clinical data and advanced training techniques, achieving superior diagnostic accuracy and explainab

Read Plain-English Story | Formal Study: “A clinical multimodal vision language foundation model with fine-grain explainability”
Rigor 92/100
Formal Study (PMID #NATURE_MED-3254811141)
Peer-Reviewed Journal (Longevity & Biotech) • Nature Medicine • 2026-10-28

Can This Approach Help? Inside the Latest Research on Editorial Expression of Concern: MicroRNA-133 controls cardiac

Nature Medicine, Published online: 28 October 2026; doi:10.1038/s41591-026-04748-1 Editorial Expression of Concern: MicroRNA-133 controls cardiac hypertrophy

Read Plain-English Story | Formal Study: “Editorial Expression of Concern: MicroRNA-133 controls cardiac hypertrophy”
Rigor 97/100
Formal Study (PMID #NATURE_MED-3271351927)
Peer-Reviewed Journal (Longevity & Biotech) • Nature Medicine • 2026-10-27

Can This Approach Help? Inside the Latest Research on Author Correction: Toripalimab or placebo plus chemotherapy as first-line

Nature Medicine, Published online: 27 October 2026; doi:10.1038/s41591-026-04751-6 Author Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial

Read Plain-English Story | Formal Study: “Author Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial”
Rigor 89/100
Formal Study (PMID #NATURE_MED-2376438322)